{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-247660","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.042367+00:00","generated_at":"2026-05-30T08:18:15.925103+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Wave Life Sciences reveals WVE-007 obesity trial startup in Q1 2025, new RNA editing programs","bullets":["WVE-007 (INHBE GalNAc-siRNA) on track for Phase 1 in Q1 2025; preclinical data show monotherapy, add-on to GLP-1s, and maintenance potential.","Three new wholly owned GalNAc-RNA editing programs: PNPLA3, LDLR, APOB targeting cardiometabolic diseases; candidate selection expected in 2025.","Wave aims to have five GalNAc-siRNA or RNA editing programs in the clinic by 2026.","Proprietary chemistry innovations (PN backbone, N3U) enhance intracellular delivery and RNA editing efficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-247660","json":"https://secwatch.observer/filing/0001193125-24-247660.json","markdown":"https://secwatch.observer/filing/0001193125-24-247660.md","text":"https://secwatch.observer/filing/0001193125-24-247660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524247660/0001193125-24-247660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524247660/d862759d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:18:15.925103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}